A 2021 meta-analysis examined the effects of glucagon-like peptide 1 (GLP-1) agonists in children less than 18 years old with obesity and/or type 2 diabetes (43). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.